Dr. Simeon George joined SR One in 2007 and leads SR One’s investment activities on the West Coast. Simeon is a director of Crispr Therapeutics (CRSP), eFFECTOR Therapeutics, Principia Biopharma, Progyny, and Birdrock. Simeon previously was a director of Genocea (GNCA), HTG Molecular (HTGM) and Semprus Biosciences (acquired by Teleflex). Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch. Simeon received his B.A. in neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa. Simeon received his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the University of Pennsylvania Wharton School.